Tenax’s Phase 3 trial missed its main goal. A 119-patient subgroup may now determine TNX-103’s future
Tenax Therapeutics has presented a deeper analysis of its Phase 3 LEVEL trial showing substantially stronger TNX-103 effects in PH-HFpEF patients with poorer baseline exercise capacity, giving the company a potential enrichment strategy for its ongoing LEVEL-2 registrational program despite LEVEL missing its primary endpoint.